【Abstract】Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory disease characterized by airflow limitation and an accelerated progressive decline in lung function, with manifestations of hypersecretion of mucus, thickening of the airway walls and destruction of alveolus, and its common outcome is pulmonary heart disease. Conventional treatments are not effective in inhibiting its progression. Mesenchymal stem cells (MSCs) can be induced to differentiate into type Ⅱ alveolar epithelial cells, and have the functions of multi-directional differentiation, anti-inflammatory, immune regulation, manipulation and recovery of adjacent cell function, showing application value in the treatment of COPD. In this article, we reviewed and analyzed the action mechanism, administration routes and clinical studies of MSCs in the treatment of COPD in order to better understand the potential and the feasibility of clinical application of MSCs.
This work was supported by the Backup Leader Project for Leading Talent Team of Heilongjiang Province [(2021) 296], the Construction Project of Second Batch Provincial Famous Traditional Chinese Medicine Expert Inheritance Workstation of Heilongjiang Province[(2021) 24] and the Cultivation Program for Young Qihuang Scholars of Heilongjiang Province (2023).
